OCT 09, 2018 4:19 PM PDT

'Copper Antibiotic Peptide' Effective in Eradicating Tuberculosis

WRITTEN BY: Nouran Amin

"Mycobacterium: the bacteria responsible for Tuberculosis", Image via National Institute of Health

The bacterium responsible for Tuberculosis has found a way to avoid antibiotics by hiding inside the macrophages which are the specific immune cells that are supposed to kill them, making treatment a challenge. However, a recent study published in ACS Infectious Diseases report a new antibiotic that can find and kill the tuberculosis bacteria exactly where they hide.

As the number one cause of death in infectious diseases worldwide, Tuberculosis infects about 25 percent of the people on the planet with most of these infections staying dormant. However, 1 in 10 infections do become active which is a fatality if left untreated.

Tuberculosis is a result of the bacterium Mycobacterium tuberculosis. Those infected with the bacterium often take a cocktail of antibiotics over the course of months in order to treat the resistant characteristics of the mycobacterium. Now, chemists at the University of Connecticut (UConn) along with colleagues from the Indian Institute of Science, the Max Planck Institute, and MIT, worked on an antibiotic that could make its way into the macrophages in order to target the Mycobacterium.

The UConn chemist Alfredo Angeles-Boza and then-graduate student, Daben Libardo, previously worked on an antibiotic derived from fish, sea squirts, and other sea creatures. These sea creatures, at least most of them, produce antibiotic peptides which are small pieces of protein-like material that are associated with an electrical charge. Copper, for example, possess the electrical charge ability that can become violent by ripping electrons away from some molecules like oxygen-containing molecules. Fortunately, since Mycobacteria contains oxygen it will be attacked by copper antibiotic peptide—completely eradicating it.

Image via theconversation.com

Surprisingly, human macrophages actually contain their very own copper that, when infected with Mycobacteria, will attack—however, they do so in a less sophisticated way. More specifically, the macrophage will enclose bacteria in a bubble and then inject copper +1 ions – which are plain copper atoms with a plus one charge (Cu+) – inside the bubble. However, the bubble method is no threat to the Mycobacterium and can handle it.

But, using the copper antibiotic peptide into smaller bubbles, the mycobacteria cannot withstand because the copper is close to the bacterium as opposed to being farther in the human macrophage bubble method.

The researchers hope to use this study and build on the chemistry to effectively make smaller molecules that can be packaged inside pills and taken like more typical antibiotics.

Source: Science Daily

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
DEC 11, 2019
Drug Discovery & Development
DEC 11, 2019
Drug To Treat Ulcerative Colitis
Biomedical researchers at the University of California—Riverside, found that the therapeutic drug ‘tofacitinib’ used in treating autoimmu...
DEC 21, 2019
Drug Discovery & Development
DEC 21, 2019
Improving Vaccines for Meningitis
Scientists at the University of Nottingham are seeking new ways to improve vaccine use in the protection against the bacterium, Neisseria meningitides that...
JAN 14, 2020
Drug Discovery & Development
JAN 14, 2020
Promising Treatment for Dementia: Antibiotics
A class of antibiotics, known as the ‘aminoglycosides’ may serve as a promising treatment for frontotemporal dementia—according to resear...
JAN 20, 2020
Cell & Molecular Biology
JAN 20, 2020
Using Modified Red Blood Cells As a Drug Delivery System
For a drug to be effective, it has to get to the right place to exert its impact....
JAN 18, 2020
Drug Discovery & Development
JAN 18, 2020
Drug Combo Targets Osteoarthritis
Individuals suffering from osteoarthritis often face challenges of limited treatment options mainly pain relievers or joint replacement surgery. However, s...
JAN 21, 2020
Drug Discovery & Development
JAN 21, 2020
Drug Targets Gastrointestinal Cancer
The FDA has recently approved Ayvakit (avapritinib) for the treatment of unresectable and metastatic gastrointestinal stromal tumor (GIST) that occurs most...
Loading Comments...